The Pharmacokinetics and Pharmacodynamics of Intravenous Uricase Multivesicular Liposomes

DENG Xue, HE Dan, XIONG Hua-rong. et al

Abstract

To determine and compare the pharmacokinetics and pharmacodynamics of uricase-multivesicular liposomes (UOMVLs) with free uricase (UOX) in rats. Methods UOMVLs were prepared by the double emulsion method and confirmed with its entrapment efficiency, size and Zeta potential. Twelve healthy rats were randomly divided into two groups: one with i.v. injection of UOMVLs, and the other with i.v. injection of UOX. Their serum activity of uricase was assayed. The pharmacokinetic parameters were calculated using software DAS 2.1.1. Another 24 male SD rats were enrolled, the rat model of hyperuricemia was established with hypoxanthine and potassium oxonate, while normal group (n=6) was set as control. Injection of UOMVLs (1 mL, 0.47 U/mL), UOX (1 mL, 0.47 U/mL) and nothiy were given 1 h later in UOMVLs group (n=6), UOX group (n=6) and model group (n=6), and their serum uric acid levels were determined 1, 2, 3, 5, 7, 9, 12, 24, 36, 48 h after the establishment of hyperuricemia model. Results The entrapment efficiency of UOMVLs was (63.75 ± 3.65)%, with an average particle size of (22.56 ± 1.70) μm and Zeta potential of (-41.81±6.59) mV. The pharmacokinetic parameters of UOMVLs and UOX were as follows, respectively: area under time-concentration curve from 0 to infinity time (AUC0-∞) (498.83±58.85) U/L·h and (28.49±9.95) U/L·h; time to peak concentration (tmax) (1.00±0.00) h and (0.00±0.00) h; peak concentration (Cmax) (73.04±6.35) U/L and (31.00±6.03) U/L; elimination half-life (t1/2) (3.49±0.80) h and (1.17±0.33) h. The relative bioavailability of UOMVLs was (1 750.90±206.56) %. UOMVLs decreased serum uric to normal in 9 h; whereas it took 48 h for the UOX group and the model group to return to normal. Conclusion UOMVLs can prolong tmax and t1/2 and improve the relative bioavailability. UOMVLs decrease serum uric acid levels in rats with hyperuricemia more effectively than UOX.

 

Keywords: Uricase, Multivesicular liposomes, Pharmacokinetics, Pharmacodynamics 

 

Full Text:

PDF


References


Me Uen РВ, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a iethniccohort: the atherosclerosis risk in communities study. Hypertension .2006 ; 48(6);1037-1042.

Hakoda M. Epidemiology of hyperuricemia and gout in Japan. Nihon Rinsho,2008;66(4); 647-652.

Chien KL. Hsu HC. Sung FC. et al. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: The Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis, 2005;183(1):147-155.

Freitas DS, Spencer PJ. Vassao RC, et al. Biochemical and biopharmaceutical properties of PEGylated uricase. Int J Pharm,2010;387( 1-2):215-222.

Tan QY. Wang N. Yang H. et al. Characterization. stabilization and activity of uricase loaded in lipid vesicles. Int J Pharm.2010;384< 1-2): 165-172.

Chen С. Han D, Zhang Y. et al. The freeze-thawed and freeze-dried stability of cytarabine-encapsulated multivesicular liposomes. Int J Pharm,2010;387( 1-2): 147-153.

Jiao YH, Sun KX, Mu HJ, et al. Preparation of sustained release multivesicular liposome for thymopentin and preliminary study oil ils pharmacokinetics in rats. Yao Xue Xue Bao,2008; 43(7):756-760.

Ramprasad MP, Amini A, Kararli T, et al. The sustained granulopoietic effect of progenipoietin encapsulated in multivesicular liposomes. Int J Pharm,2003;261( 1-2) ;93-103.

Tan QY, Zhang JQ. Wang N, et al. Uricase from Bacillus fastidious loaded in alkaline enzymosomes; enhanced biochemical and pharmacological characteristics in hypouricemic rats. Eur J Pharm Biopharm,2012;82(l) :43-48.

Poznansky MJ. In vitro and in vivo activity of soluble cross- linked uricasealbumin polymers; a model for enzyme therapy. Life Sci. 1979;24(2): 153-158.

OLoughlin JA, Bruder JM. Lysaght MJ. Degradation of low molecular weight uremic solutes by oral delivery of encapsulated enzymes. ASAIO J ,2004;50(2);253-260.

Sankaram M. A lipid based depot for sustained release drug delivery. Prog Lipid Res,2002;41 (5) :392-406.


Refbacks

  • There are currently no refbacks.